# TriOptoTec

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trioptotec

- Industry: Chemicals
- Headquarters: Regensburg, Germany
- Website: www.dyphox.com
- Total disclosed funding: $2.2M
- Latest round: Series C (Apr 21, 2020)
- Investors on record: 2

## About

TriOptoTec GmbH focuses on developing patented photocatalysts and formulations for biocidal and chemical applications, enhancing sanitation and chemical challenges across various industries.Founded in 2010 and headquartered in Regensburg, Germany, TriOptoTec GmbH specializes in advanced photocatalytic technologies. The company has engaged in a total of 3 investment deals, with its most recent funding round occurring on April 21, 2020. This round was a Series B funding of EUR 2.000 mn from investors Bayern Kapital and CD-Venture, bringing the total amount raised to EUR 2.000 mn and its current valuation to EUR 11.684 mn. Xaver Auer serves as the CEO of the company.TriOptoTec GmbH specializes in the development of advanced patented photocatalysts, coatings, and formulations designed for biocidal and chemical applications. Their core product offerings leverage photodynamics to enhance oxidation processes, effectively addressing hygiene gaps and various chemical challenges faced by industries. These products cater to a diverse client base, including businesses seeking innovative solutions for sanitation and chemical processing across sectors such as healthcare, food safety, and industrial applications. The geographical markets served by Dyphox extend throughout Europe and other regions where there is a demand for advanced biocidal and photocatalytic technologies.TriOptoTec GmbH's revenue model primarily centers around B2B transactions, providing innovative products directly to businesses that require advanced hygiene and chemical solutions. The company's sales structure includes partnerships with distributors and retailers, facilitating widespread product availability in relevant markets. While specific pricing details for their offerings are not publicly disclosed, the company engages in structured agreements that allow clients to procure its flagship photocatalysts and coatings based on their specific application needs, thereby enhancing operational efficiency and hygiene standards.In April 2020, TriOptoTec GmbH secured Series C funding from returning investors Bayern Kapital and CD-Venture, which will support the development of new products and expansion into additional European markets. The company plans to launch several innovative photocatalytic products in the upcoming year, aiming to address emerging hygiene needs and chemical processing challenges. This strategic funding will help facilitate these initiatives and further enhance the company’s market presence.

## Funding rounds

- Series C, Apr 21, 2020 — Bayern Kapital, CD-Venture
- Series B, Feb 3, 2020, $2.2M — Bayern Kapital, CD-Venture
- Series A, Jun 1, 2017 — Bayern Kapital

## Investors

- Bayern Kapital (https://capitalatlas.ai/funds/bayern-kapital) — Series A, Series B, Series C
- CD-Venture (https://capitalatlas.ai/funds/cd-venture) — Series B, Series C